Volume 92 Issue 10 | pp. 22-24
Issue Date: March 10, 2014

Pharma Growth Still Stagnant

Major drug firms continued to see declines in 2013, while biotech companies shined
Department: Business
Keywords: pharmaceuticals, biotech, M&A, earnings

Big pharmaceutical companies continue to suffer the ill effects of their decades-long addiction to blockbuster drugs. Many of the multi-billion-dollar sellers that once fueled double-digit profit growth lost patent protection years ago, but companies still have not managed to replace the lost revenues. Last year was no different: Most firms sustained themselves on older drugs still protected by patents.

After a rocky first half, marked for many companies by declines in sales and earnings, the . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society